New Rufomycins from Streptomyces atratus MJM3502 Expand Anti- Mycobacterium tuberculosis Structure-Activity Relationships

Org Lett. 2022 Oct 14;24(40):7265-7270. doi: 10.1021/acs.orglett.2c02493. Epub 2022 Oct 4.

Abstract

Four new rufomycins, compounds 1-4, named rufomycins 56, 57, 58, and 61, respectively, exhibiting new skeletal features, were obtained from Streptomyces atratus strain MJM3502 and were fully characterized. Compounds 1 and 2 possess a 4-imidazolidinone ring not previously encountered in this family of cyclopeptides, thereby resulting in a [5,17] bicyclic framework. The in vitro anti-Mycobacterium tuberculosis potency of compounds 3 and 4 is remarkable, with minimum inhibitory concentration values of 8.5 and 130 nM, respectively.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents* / chemistry
  • Antitubercular Agents* / pharmacology
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis* / drug effects
  • Oligopeptides* / chemistry
  • Oligopeptides* / pharmacology
  • Peptides, Cyclic / chemistry
  • Streptomyces* / chemistry
  • Structure-Activity Relationship

Substances

  • Antitubercular Agents
  • Oligopeptides
  • Peptides, Cyclic
  • rufomycin

Supplementary concepts

  • Streptomyces atratus